Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Joan Montero1,2,3, Cécile Gstalder2,4, Daniel J Kim5
1Division of Hematologic Neoplasia/Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, 02115, MA, USA.
Abstract:
Most targeted cancer therapies fail to achieve complete tumor regressions or attain durable remissions. To understand why these treatments fail to induce robust cytotoxic responses despite appropriately targeting oncogenic drivers, here we systematically interrogated the dependence of cancer cells on the BCL-2 family of apoptotic proteins after drug treatment. We observe that multiple targeted therapies, including BRAF or EGFR inhibitors, rapidly deplete the pro-apoptotic factor NOXA, thus creating a dependence on the anti-apoptotic protein MCL-1. This adaptation requires a pathway leading to destabilization of the NOXA mRNA transcript. We find that interruption of this mechanism of anti-apoptotic adaptive resistance dramatically increases cytotoxic responses in cell lines and a murine melanoma model. These results identify NOXA mRNA destabilization/MCL-1 adaptation as a non-genomic mechanism that limits apoptotic responses, suggesting that sequencing of MCL-1 inhibitors with targeted therapies could overcome such widespread and clinically important resistance.
Insights
Targeted cancer therapies often fail due to adaptive resistance. This study reveals that depleting NOXA protein after drug treatment creates a dependence on MCL-1, hindering cancer cell death. Blocking this adaptive resistance enhances treatment effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Targeted cancer therapies frequently exhibit limited efficacy, failing to induce complete tumor regression or durable remissions.
- The underlying mechanisms of adaptive resistance that limit the cytotoxic responses of cancer cells to targeted therapies remain incompletely understood.
Purpose of the Study:
- To systematically investigate the dependence of cancer cells on BCL-2 family apoptotic proteins following targeted drug treatment.
- To elucidate the non-genomic adaptive mechanisms that confer resistance to targeted cancer therapies.
Main Methods:
- Systematic interrogation of cancer cell dependence on BCL-2 family proteins post-drug treatment.
- Analysis of targeted therapy effects (BRAF, EGFR inhibitors) on apoptotic factors, specifically NOXA and MCL-1.
- Investigation of the NOXA mRNA transcript destabilization pathway and its role in adaptive resistance.
- Evaluation of interrupting this resistance mechanism in cell lines and a murine melanoma model.
Main Results:
- Multiple targeted therapies rapidly deplete the pro-apoptotic factor NOXA, inducing cancer cell dependence on the anti-apoptotic protein MCL-1.
- This adaptive resistance is mediated by a pathway leading to the destabilization of the NOXA mRNA transcript.
- Interruption of this NOXA mRNA destabilization/MCL-1 adaptation mechanism significantly enhanced cytotoxic responses in preclinical models.
Conclusions:
- NOXA mRNA destabilization and subsequent MCL-1 adaptation represent a critical non-genomic mechanism limiting apoptotic responses to targeted therapies.
- Targeting this adaptive resistance pathway, potentially through the sequencing of MCL-1 inhibitors with existing targeted therapies, offers a promising strategy to overcome clinical resistance.
More Related Videos
Related Concept Videos
02:31Nuclear Export of mRNA
02:27Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
02:27Nonsense-mediated mRNA Decay
02:56Treatment Resistant Cancers
02:51mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
01:22MicroRNAs